Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Alendronate should be considered as an alternative therapy of osteogenesis imperfecta (OI)
because it significantly increased areal bone mineral density (BMD) and its Z score,
decreased fracture incidence, inhibited bone resorption biomarkers. Alendronate exerted
beneficial roles in different age brackets, especially in young patients with OI.